GlassScriptPhysician profile
Kelsey Ackerman
NPI 1952893539
$1,346.21
in general payments reported to CMS, 2019-2025
24 companies · $82.01 in 2025
The $82.01 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $434 · 2022: $557 · 2023: $170 · 2024: $103 · 2025: $82.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.45 | 2022-2025 | Qulipta |
| Janssen Pharmaceuticals, INC | $180.11 | 2021-2024 | Spravato |
| Amarin Pharma, INC. | $136.34 | 2021-2022 | |
| Lilly USA, LLC | $113.12 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.26 | 2021-2023 | |
| Novo Nordisk INC | $79.33 | 2022-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $41.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.21 | 2021-2022 | |
| Organon LLC | $34.82 | 2025 | Nexplanon |
| Esperion Therapeutics, INC. | $33.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $32.50 | 2021 | |
| Idorsia Pharmaceuticals US INC | $31.87 | 2023-2024 | Quviviq |
| Corcept Therapeutics | $30.66 | 2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $30.24 | 2021 | |
| Exact Sciences Corporation | $29.43 | 2025 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $21.74 | 2023 | Nuzyra |
| Antares Pharma, INC. | $21.28 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.39 | 2021 | |
| Nevro Corp. | $15.82 | 2023 | Senza |
| Amgen INC. | $15.14 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.02 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.37 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.